BXTAccelyon

Protected: Low dose rate brachytherapy for localised carcinoma of the prostate

By BXTAccelyon August 11, 2021 No Comments

About Author

BXTAccelyon

BXTAccelyon (BXTA) is the leading low-dose rate brachytherapy (LDR-B) partner to hospitals and clinics worldwide, and distribution partner for the PrecisionPoint™ freehand transperineal prostate biopsy system.

This post is password protected. Enter the password to view comments.

About Author

Related Posts

ASCO GU 2026: Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery

Model predicts long term mortality risk from prostate cancer

New prostate cancer trial seeks to reduce toxicity without sacrificing efficacy